Serena Di Cosimo
The Breast Cancer Research Foundation
CancerInternal medicineSurgeryOncologyMetastatic breast cancerChemotherapyLapatinibNeoadjuvant therapyTrastuzumabEpirubicinGynecologyIn patientEarly breast cancerCancer researchRadiation therapyBreast cancerClinical trialMedicineBiologyGastroenterology
144Publications
31H-index
6,148Citations
Publications 142
Newest
#1Jose Perez-GarciaH-Index: 22
#2Geraldine Gebhart (ULB: Université libre de Bruxelles)H-Index: 10
Last. Trial InvestigatorsH-Index: 1
view all 23 authors...
Summary Background Several de-escalation approaches are under investigation in patients with HER2-positive, early-stage breast cancer. We assessed early metabolic responses to neoadjuvant trastuzumab and pertuzumab using 18F-fluorodeoxyglucose (18F-FDG)-PET (18F-FDG-PET) and the possibility of chemotherapy de-escalation using a pathological response-adapted strategy. Methods We did a multicentre, randomised, open-label, non-comparative, phase 2 trial in 45 hospitals in Spain, France, Belgium, Ge...
Source
#1Carolina ReduzziH-Index: 6
#2Serena Di CosimoH-Index: 31
Last. Vera CappellettiH-Index: 22
view all 16 authors...
The clinical relevance of circulating tumor cell clusters (CTC-clusters) in breast cancer (BC) has been mostly studied using the CellSearch®, a marker-dependent method detecting only epithelial-enriched clusters. However, due to epithelial-to-mesenchymal transition, resorting to marker-independent approaches can improve CTC-cluster detection. Blood samples collected from healthy donors and spiked-in with tumor mammospheres, or from BC patients, were processed for CTC-cluster detection with 3 tec...
Source
#1Andrea MalfettoneH-Index: 3
#2Serena Di CosimoH-Index: 31
Last. J. CortesH-Index: 2
view all 9 authors...
In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insights. Though limited by sample size, our data emphasize the importance of quickly adopting measures that first prioritize patient safety and data validity, then consider contingency measures such as tele...
Source
#1Maria Alice Franzoi (ULB: Université libre de Bruxelles)H-Index: 5
#2Daniel Eiger (ULB: Université libre de Bruxelles)H-Index: 7
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 60
view all 14 authors...
BACKGROUND There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors. METHODS Pooled analysis of individual patient-level data from MONARCH 2 and 3 trials. Patients were classified according to baseline BMI into underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30 kg/m2) and divided into two treatment groups: abemaciclib +...
4 CitationsSource
#1Catherine DeprettoH-Index: 2
#2Alessandro Liguori (University of Milan)H-Index: 2
Last. Gianfranco ScaperrottaH-Index: 8
view all 7 authors...
PURPOSE To investigate the agreement between automated breast ultrasound (ABUS) and hand-held ultrasound (HHUS) in surveillance of women with a history of breast cancer in terms of recurrences or new ipsilateral or contralateral breast cancer. METHODS The institutional review board approved this retrospective study and informed consent was waived. From April to June 2016, women with dense breasts undergoing annual surveillance with mammography and HHUS after breast-conserving surgery were offere...
Source
#1Nuria Chic (The Breast Cancer Research Foundation)H-Index: 7
#2Stephen J Luen (University of Melbourne)H-Index: 12
Last. Sherene Loi (University of Melbourne)H-Index: 85
view all 14 authors...
In early-stage HER2-positive breast cancer, biomarkers that guide de-escalation and/or escalation of systemic therapy are needed. CelTIL score is a novel, combined biomarker based on stromal tumor-infiltrating lymphocytes and tumor cellularity and determined in tumor biopsies at week 2 of anti-HER2 therapy only. We evaluated the prognostic value of CelTIL in 196 patients with early-stage HER2-positive disease treated with standard trastuzumab-based chemotherapy in the NeoALTTO phase III trial. U...
Source
#1Serena Di CosimoH-Index: 31
Last. Marco DanovaH-Index: 28
view all 33 authors...
Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT) are critical to their management through the evolving COVID-19 pandemic. The AIOM-L CORONA was a multicenter, observational, ambispective, cohort study, with the intended participation of 26 centers in the Lombardy region (Italy). A total of 231 cases were included between March and Se...
Source
#1Nuria ChicH-Index: 7
#2Stephen J LuenH-Index: 12
Last. Sherene LoiH-Index: 85
view all 14 authors...
Source
#1Jose Perez-GarciaH-Index: 22
Last. Javier CortesH-Index: 76
view all 22 authors...
Background: P led to a meaningful improvement in clinical outcomes when used in combination with endocrine therapy for first- or later-line regimen in HR[+]/HER2[-] MBC. Grade 3-4 neutropenia was the most common adverse event (AE) in the P-containing regimens. Although venous thromboembolic events (VTE) have been rarely reported in registrational trials, a systematic review and meta-analysis of randomized controlled trials demonstrated a higher rate of these AEs. Moreover, rare but severe cases ...
Source
#1Serena Di CosimoH-Index: 31
#2Luca PorcuH-Index: 16
Last. Fatima Cardoso (Champalimaud Foundation)H-Index: 77
view all 3 authors...
Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic management of HR+/HER2-advanced breast cancer by prolonging progression-free and overall survival when given in combination with endocrine therapy. In this article, available data from PALLAS and mona...
Source